Clinical trials: Polymyalgia Rheumatica
Giant Cell Arteritis, Temporal Arteritis
Clonal Hematopoiesis in Giant Cell Arteritis
The goal of this clinical trial is to verify whether CHIP is correlated with the clinical, instrumental, and histological characteristics of GCA, and to characterize the pathogenetic effects of clonal hemopoiesis on vasculitis.
- Conditions
- Giant Cell Arteritis, Temporal Arteritis, Clonal Hematopoiesis of Indeterminate Potential, Horton Disease
- Trial name
- CH-GCA (NCT06244069)
- Testing
- Temporal arterial biopsy, Whole exome sequencing, Single cell transcriptomics
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- ASST Fatebenefratelli Sacco
Polymyalgia Rheumatica, Giant Cell Arteritis
Polymyalgia Rheumatica and Giant Cell Arteritis
The purpose of this study is to delineate the association of the 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) detected vasculitis pattern of the large vessels (PET positivity) and the…
- Trial name
- NCT02985424
- Testing
- 18F-FDG PET/CT
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Svendborg Hospital
Chronic Coronary Syndrome, Heart Failure
COVID-19 Related Lockdown Effects On Chronic Diseases
The containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation.
- Conditions
- Chronic Coronary Syndrome, Heart Failure, AMD and Macular Edema, Chronic Respiratory Failure
- Trial name
- CLEO-CD (NCT04390126)
- Testing
- life questionnaires, questionnaire
- Where
- France
- Volunteers
- 1,343 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Giant Cell Arteritis, Acute Phase
Study of Circulating Microparticles in Giant Cell Arteritis
To demonstrate that microparticles (MPs), having a powerful procoagulant potential, are in larger amounts in the blood of patients with histologically proven giant cell arteritis (GCA), compared with patients matched for age, sex…
- Trial name
- MicroGiant (NCT02333708)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Polymyalgia Rheumatica, Inflammatory Rheumatism
Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica (JADORE)
Pseudo-rheumatoid arthritis (PRA) is a common inflammatory rheumatic disease of the elderly, characterized by inflammatory shoulder and/or hip pain.
- Trial name
- JADORE (NCT07132164)
- Testing
- biobank sample collection
- Where
- 30 sites in France
- Volunteers
- 400 people
- Sponsor
- University Hospital, Brest
Horton's Disease
Study of Phenotypic and Functional Characteristics of Regulatory T Lymphocytes in Horton's Disease
Giant cell arteritis (GCA) is the most frequent vascularitis after 50 years of age The investigators recently showed that GCA was accompanied by an elevation in Th1 and Th17 response [1].
- Trial name
- ACG et TREG (NCT02857192)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Polymyalgia Rheumatica
Treatment With Leflunomide in Patients With Polymyalgia Rheumatica
Over the last decades outcome has greatly improved for rheumatoid arthritis (RA) and spondyloarthritis (SpA). This is in sharp contrast to the situation for polymyalgia rheumatica (PMR), with a lifetime prevalence of 2.4% for…
- Trial name
- PMRLEFRCT (NCT03576794)
- Testing
- Leflunomide 20 mg, Prednisolone
- Where
- 2 sites in Netherlands
- Volunteers
- 94 people
- Sponsor
- Elisabeth Brouwer
Giant Cell Arteritis
Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering
Corticosteroid therapy has always been the standard treatment for giant cell arteritis (GCA), with very good initial clinical efficacy but a high relapse rate when it declines.
- Trial name
- CORTODOSE (NCT04012905)
- Testing
- Corticosteroids for Systemic Use
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Caen
Giant Cell Arteritis
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Primary Objective: To evaluate the efficacy of sarilumab in participants with giant cell arteritis (GCA) as assessed by the proportion of participants with sustained remission for sarilumab compared to placebo, in combination…
- Trial name
- NCT03600805
- Testing
- Sarilumab SAR153191, Prednisone
- Where
- 61 sites in United States, Argentina and 19 more
- Volunteers
- 83 people
- Sponsor
- Sanofi
Polymyalgia Rheumatica
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse
Polymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing…
- Trial name
- REDUCE-PMR-2 (NCT05533164)
- Testing
- Rituximab
- Where
- Netherlands
- Volunteers
- 174 people
- Sponsor
- Sint Maartenskliniek
Giant Cell Arteritis
Tocilizumab Plus a Short Prednisone Taper for GCA
This is an open-label pilot study of tocilizumab (TCZ) 162 mg weekly administered subcutaneously for 52 weeks in combination with 8 weeks of oral prednisone.
- Trial name
- NCT03726749
- Testing
- Tocilizumab, Prednisone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Polymyalgia Rheumatics (PMR)
Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia Rheumatica
The study intends to explore the efficacy and safety of Ivarmacitinib in therapy for polymyalgia rheumatica through a multicenter, randomized, double-blind, placebo-controlled study, and to explore the effectiveness of…
- Trial name
- NCT07266168
- Testing
- Ivarmacitinib tablet
- Volunteers
- 80 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Giant Cell Arteritis, Polymyalgia Rheumatica
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics [PK]) and whether it will be safe and tolerable after multiple doses of i.v.
- Trial name
- NCT06130540
- Testing
- Secukinumab
- Where
- 19 sites in United States, Czechia and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals